Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Revisits Wellbutrin Generics – Again; Will Teva Fund A High-Dose Study?

Executive Summary

As FDA considers how best to address continued concerns about generics for Wellbutrin XL (bupropion extended-release tablets), one issue it may wrestle with is whether it should conduct bioequivalence studies at the highest dose, 300 mg, which has a higher risk of seizures

You may also be interested in...



Generic Approval Standards For Vancomycin Tightened In FDA Draft Guidance

FDA has tightened approval standards for generic oral vancomycin, but appears to have left enough latitude in bioequivalence testing requirements to not greatly impede generic competition

Generic Approval Standards For Vancomycin Tightened In FDA Draft Guidance

FDA has tightened approval standards for generic oral vancomycin, but appears to have left enough latitude in bioequivalence testing requirements to not greatly impede generic competition

Generic Firms Object To Policy Behind Residual Solvents Deficiency Letters

FDA's Office of Generic Drugs has interpreted a new pharmacopoeial standard for residual solvents in an unexpectedly rigorous manner, rejecting dozens of applications and raising the ire of generic drug manufacturers

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS050143

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel